Literature DB >> 8891167

In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite.

A J Chaput1, R D'Ambrosio, G D Morse.   

Abstract

This study was performed to determine delavirdine protein-binding characteristics as well as those of its N-dealkylated metabolite (N-DLV). Initial studies of 36 microM delavirdine and 30 microM N-DLV in solutions of plasma, albumin 4 g%, alpha-1-acid glycoprotein (AAG) 100 mg% or immune globulin (IVIG) 5 g% were conducted. Delavirdine (12, 36 and 73 microM) and N-DLV (10, 30 and 60 microM) were then studied alone and in combination in plasma and various concentrations of albumin. Studies were done in triplicate using equilibrium dialysis. The mean delavirdine fraction unbound (fu) in plasma, albumin, IVIG and AAG was 0.013, 0.033, 0.752 and 0.912 while the mean fu of N-DLV in these same protein solutions was 0.139, 0.195, 0.329 and 0.359. In plasma and albumin, a greater fu was observed at higher delavirdine concentrations and no significant changes in fu were noted with the addition of N-DLV. An increase in delavirdine fu was noted as the albumin concentrations decreased. The fu of N-DLV increased significantly as the concentration of albumin decreased as well as with decreasing N-DLV concentration. The potential implications of extensive delavirdine binding to plasma proteins, primarily albumin, are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891167     DOI: 10.1016/0166-3542(95)00984-1

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  5 in total

Review 1.  Delavirdine: clinical pharmacokinetics and drug interactions.

Authors:  J Q Tran; J G Gerber; B M Kerr
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Delavirdine: a review of its use in HIV infection.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.

Authors:  P F Smith; R DiCenzo; G D Morse
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients.

Authors:  Gene D Morse; Susan E Cohn; Mark J Shelton; Carol Greisberger; Steven R Cox; Andrew A Della-Coletta; William W Freimuth; Richard C Reichman
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 5.  Identification of Potential Drug Targets of Broad-Spectrum Inhibitors with a Michael Acceptor Moiety Using Shotgun Proteomics.

Authors:  Hao-Wei Chu; Bidyadhar Sethy; Pei-Wen Hsieh; Jim-Tong Horng
Journal:  Viruses       Date:  2021-09-02       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.